Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients

被引:0
|
作者
Zhang, Xiaomin [1 ]
Yang, Jieli [1 ]
Chen, Sai [1 ]
Liu, Chang [1 ]
Wang, Zhenhua [1 ]
Ren, Hefei [1 ]
Zhou, Lin [1 ]
机构
[1] Naval Med Univ, Shanghai Changzheng Hosp, Dept Lab Med, 415 Fengyang Rd, Shanghai 200003, Peoples R China
基金
中国国家自然科学基金; 芬兰科学院;
关键词
Hypertension; Multiple myeloma; Progression-free survival; Risk stratification; BLOOD-PRESSURE; PARATHYROID-HORMONE; CANCER; RISK; CELLS; INTERLEUKIN-6; INFLAMMATION; MEDICATIONS; CALCIUM;
D O I
10.1007/s11239-022-02653-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. We collected data from 228 newly diagnosed patients with MM and found that 71 (31.1%) had pre-existing hypertension. The impact of pre-existing hypertension on MM patients was determined by evaluating progression-free survival (PFS). Kaplan-Meier analyses revealed a significantly lower PFS in the pre-existing hypertension group than their non-hypertensive counterparts (median 22.6 vs 34.8 months, respectively). The multivariable Cox proportional hazards model showed that pre-existing hypertension was an independent risk factor for PFS reduction in MM patients. Moreover, the risk of disease progression in MM patients with pre-existing hypertension was higher than in non-hypertension comparator patients (hazard ratio 1.735, 95% confidence interval 1.261-2.387). In MM patients with pre-existing hypertension, Kaplan-Meier analyses found that those with a higher risk of hypertension had a significantly shorter PFS than those with lower risk (median 19.3 vs 25.4 months, respectively). However, multivariate Cox regression analysis showed that the risk stratification of hypertension was not an independent risk factor for poor PFS in MM patients with pre-existing hypertension. Our study demonstrates that pre-existing hypertension was significantly associated with a lower PFS in newly diagnosed MM patients.
引用
收藏
页码:542 / 549
页数:8
相关论文
共 50 条
  • [31] Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients
    Rebmann, Vera
    Schuett, Philipp
    Brandhorst, Dieter
    Opalka, Bertram
    Moritz, Thomas
    Nowrousian, Mohammad Reza
    Grosse-Wilde, Hans
    CLINICAL IMMUNOLOGY, 2007, 123 (01) : 114 - 120
  • [32] The Impact of Focal Lesions on Overall and Progression-free Survival in Multiple Myeloma
    Kirkizlar, Tugcan Alp
    Kirkizlar, Onur
    Soyluoglu, Selin
    Umit, Elif Gulsum
    Ustun, Funda
    Demir, Ahmet Muzaffer
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2024, 39 (05): : 353 - 359
  • [33] Immunoglobulin Recovery after ASCT for Patients with Multiple Myeloma: Impact on Overall Survival and Progression-Free Survival
    Jimenez-Zepeda, Victor
    Duggan, Peter
    Neri, Paola
    Chaudhry, Ahsan
    Tay, Jason
    Bahlis, Nizar J.
    BLOOD, 2016, 128 (22)
  • [34] Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study
    Gordan, Lucio Navarro
    Tan, Carlyn Rose
    Vescio, Robert
    Ye, Jing Christine
    Schinke, Carolina
    Medhekar, Rohan
    Fu, Alex Z.
    Lafeuille, Marie-Helene
    Thompso-Leduc, Philippe
    Khare, Vipin
    Reitan, John
    Milkovich, Gary
    Kaila, Shuchita
    Davies, Faith
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (01): : 55 - 63
  • [35] Construction and validation of an 18F-FDG-PET/CT-based prognostic model to predict progression-free survival in newly diagnosed multiple myeloma patients
    Dong, Xiaoqing
    Wang, Ruoyi
    Ying, Xiuhua
    Xu, Jiaxuan
    Yan, Jie
    Xu, Peipei
    Peng, Yue
    Chen, Bing
    HEMATOLOGY, 2024, 29 (01)
  • [36] Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study
    Gordan, Lucio
    Tan, Carlyn Rose
    Vescio, Robert
    Ye, Jing Christine
    Schinke, Carolina
    Medhekar, Rohan
    Fu, Alex
    Lafeuille, Marie-Helene
    Thompson-Leduc, Philippe
    Khare, Vipin
    Reitan, John
    Milkovich, Gary
    Kaila, Shuchita
    Davies, Faith
    Usmani, Saad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S98 - S98
  • [37] Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study
    Gordan, Lucio
    Tan, Carlyn Rose
    Vescio, Robert
    Ye, Jing Christine
    Schinke, Carolina
    Medhekar, Rohan
    Fu, Alex Z.
    Lafeuille, Marie-Helene
    Thompson-Leduc, Philippe
    Khare, Vipin
    Reitan, John
    Milkovich, Gary
    Kaila, Shuchita
    Davies, Faith
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S502 - S502
  • [38] Monocytosis at Diagnosis Is Associated with Decreased Overall Survival in Patients with Newly Diagnosed Multiple Myeloma
    Edwards, Camille V.
    Yildirim, Cenk
    Fillmore, Nathanael
    Munshi, Nikhil C.
    BLOOD, 2020, 136
  • [39] Levels of Uninvolved Immunoglobulin Predict Clinical Status and Progression-Free Survival for Multiple Myeloma Patients
    Harutyunyan, Nika M.
    Vardanyan, Suzie
    Ghermezi, Michael
    Gottlieb, Jillian
    Berenson, Ariana
    Andreu-Vieyra, Claudia
    Tang, George
    Sanchez, Eric
    Li, Mingjie
    Wang, Cathy
    Ben-Zvi, Joseph
    Garzio, Gigi
    Chen, Haiming
    Finlay, Judith
    Berenson, James R.
    BLOOD, 2014, 124 (21)
  • [40] Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
    Avet-Loiseau, Herve
    Fonseca, Rafael
    Siegel, David
    Dimopoulos, Meletios A.
    Spicka, Ivan
    Masszi, Tamas
    Hajek, Roman
    Rosinol, Laura
    Goranova-Marinova, Vesselina
    Mihaylov, Georgi
    Maisnar, Vladimir
    Mateos, Maria-Victoria
    Wang, Michael
    Niesvizky, Ruben
    Oriol, Albert
    Jakubowiak, Andrzej
    Minarik, Jiri
    Palumbo, Antonio
    Bensinger, William
    Kukreti, Vishal
    Ben-Yehuda, Dina
    Stewart, A. Keith
    Obreja, Mihaela
    Moreau, Philippe
    BLOOD, 2016, 128 (09) : 1174 - 1180